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Abstract
Detection of specific antibodies against hepatitis C virus (HCV) is the most widely available test for viral diagnosis and
monitoring of HCV infections. However, narrowing the serologic window of anti-HCV detection by enhancing anti-HCV IgM
detection has remained to be a problem. Herein, we used LD5, a novel evolved immunoglobulin-binding molecule (NEIBM)
with a high affinity for IgM, to develop a new anti-HCV enzyme-linked immunosorbent assay (ELISA) using horseradish
peroxidase-labeled LD5 (HRP-LD5) as the conjugated enzyme complex. The HRP-LD5 assay showed detection efficacy that is
comparable with two kinds of domestic diagnostic kits and the Abbott 3.0 kit when tested against the national reference
panel. Moreover, the HRP-LD5 assay showed a higher detection rate (55.9%, 95% confidence intervals (95% CI) 0.489, 0.629)
than that of a domestic diagnostic ELISA kit (Chang Zheng) (53.3%, 95% CI 0.463, 0.603) in 195 hemodialysis patient serum
samples. Five serum samples that were positive using the HRP-LD5 assay and negative with the conventional anti-HCV
diagnostic ELISA kits were all positive for HCV RNA, and 4 of them had detectable antibodies when tested with the
established anti-HCV IgM assay. An IgM confirmation study revealed the IgM reaction nature of these five serum samples.
These results demonstrate that HRP-LD5 improved anti-HCV detection by enhancing the detection of anti-HCV IgM, which
may have potential value for the early diagnosis and screening of hepatitis C and other infectious diseases.
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Introduction
Serologic determination of specific antibodies against hepatitis C
virus (HCV) and detection of viral RNA are the mostwidely available
tests for viral diagnosis and monitoring of HCV infection. Since the
cloning of HCV in 1989 [1], several generations of anti-HCV
enzyme immunoassay (EIA) have been developed [2–4]. The
sensitivity of the third-generation EIA was greater than 98%, a
significant improvement over the approximately 80% sensitivity of
the first-generation EIA, and the average seroconversion period of 10
to 16 weeks using first-generation EIA was shortened to approxi-
mately 8 weeks [3–7]. This improvement was mostly attributed to the
addition of HCV coating antigens, core proteins (c22–3), NS3 (c33c)
andNS5totheNS4protein(c100–3)usedin the first-generation EIA.
However, this 8 weeks serologic window of anti-HCV detection
remains to be a problem for early viral diagnosis and efficient
screening of blood donors. It is difficult to narrow the serologic
window significantly by adding new HCV coating antigens. In an
individual’s response against virus infection, immunoglobulin M
(IgM) antibodies appear first within the first week. Therefore, it
should be possible to narrow the serologic window of anti-HCV
detection by enhancing the anti-HCV IgM detection.
Novel evolved immunoglobulin-binding molecules (NEIBMs),
characterized by MDPL-MDPA (MDPL, mono-domain of protein
L; MDPA, mono-domain of protein A), have been generated by in
vitro molecular evolution [8,9]. These proteins have been shown to
simultaneously bind to k light chains and VH3 heavy chains of
immunoglobulin and have shown high affinity for IgM in addition
to IgG. In this study, we developed a new anti-HCV enzyme-linked
immunosorbent assay (ELISA) by using horseradish peroxidase-
labeled LD5 (HRP-LD5), a NEIBM, as the conjugated enzyme
complex. Comparison studies using Chinese hemodialysis samples
demonstrated that HRP-LD5 based assay can improve anti-HCV
detection because of its enhanced anti-HCV IgM detection efficacy.
Materials and Methods
Ethics statement
All aspects of the study were approved by the Shanghai Society
of Medical Ethics, China and the Changhai Hospital Ethics
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China. Written informed consent was obtained from all partici-
pants in the study.
Serum samples
A total of 195 hemodialysis patient serum samples were
obtained from the hemodialysis room of Zhongshan Hospital of
Fudan University (Shanghai, China; 1997). All samples were
aliquoted upon receipt and stored at 220uC. The national
reference panel for anti-HCV (Lot No. 0501) was from the
National Institute for the Pharmaceutical and Biological Products
of China and consists of 30 anti-HCV-positive human plasma
samples and 30 HCV-negative serum samples that have been
solvent-detergent treated. Two hundred serum specimens from
healthy blood donors (Changhai Hospital, Second Military
Medical University, Shanghai, China) were used to establish a
cut-off value for the new diagnostic method.
Novel evolved immunoglobulin-binding molecule
The novel evolved immunoglobulin-binding molecule (NEIBM)
LD5 (B3-D-B3-D-B3) was previously generated with the charac-
teristic structure of alternately arranged Finegoldia magna protein L
B3 domains (B3) and staphylococcal protein A (SpA) D domains
(D). LD5 showed substantially higher affinity for IgG-F(ab’)2, IgM,
and IgA than did either 4L (B3-B3-B3-B3) or SpA, which creates
synergistic double-site binding sites to the VH3 and Vk regions of
the fragment of antigen binding [8].
Diagnostic ELISA kits and reagents
Anti-HCV diagnostic ELISA kits were purchased from Shanghai
Chang Zheng Co. (China), Shanghai Ke Hua Bio-engineering Co.,
Ltd. (China) and Abbott Diagnostics (Abbott anti-HCV 3.0 kits,
Chicago, IL, USA). Human IgG (hIgG), human IgM (hIgM),
human IgA (hIgA), goat anti-human IgG, horseradish peroxidase
(HRP), HRP-conjugated streptavidin, HRP-conjugated goat anti-
human polyclonal polyvalent immunoglobulins (G, A, M) (HRP-
goat anti-human PcAb), HRP-conjugated anti-hIgG and HRP-
conjugated anti-hIgM were obtained from Sigma (St. Louis, MO,
USA). hIgG, hIgM and hIgA antibodies were biotinylated using
biotinyl-N-hydroxy-succinimide (Pierce, Rockford, IL, USA) in our
lab (data not shown). b-mercaptoethanol (BME) was from Janssen
Chimica (Geel, Belgium). Prokaryotic expressed SpA (Genbank:
P02976) was kindly provided by Shanghai Fudan-Zhangjiang Bio-
Pharmaceutical Co. Ltd. (Shanghai, China). HCV Nucleocapsid/
NS3/NS4/NS5 recombinant proteins were from GenWay Biotech
Inc. (CA, USA).
Biosensor analyses of LD5
The binding properties of LD5 to hIgG/hIgM/hIgA were
studied by surface plasmon resonance (SPR) using a Biacore 3000
instrument (Biacore, Uppsala, Sweden). Briefly, 1 mg/ml hIgG,
hIgM, or hIgA resuspended in 10 mM sodium acetate (1:5
diluted), pH 5.0, 4.5, or 4.0, was coupled to CM-5 sensor chips
using amine-coupling chemistry. The association and dissociation
were measured at a flow rate of 40 ml/min using NaCl/HEPES
supplemented with 0.005% surfactant P20 as flow buffer. The
sensor-chip surfaces were regenerated with 100 mM alanine-HCl
(pH 2.5).
HRP labeling
HRP-labeled LD5 (HRP-LD5) was prepared by using sodium
periodate according to the following procedure. Five milligrams of
HRP was dissolved in 1 ml distilled water, and then 200 mlo fa
freshly prepared solution of 0.1 M sodium periodate was added.
After stirring for 20 min in the dark, the above solution was
dialyzed overnight against a 1 mM sodium acetate buffer (pH 4.4)
at 4uC, then 1 ml of a 5 mg/ml LD5 in a phosphate-buffered
saline (PBS) (pH 7.2) was added immediately after adding a 20 ml
of a 0.2 M carbonate buffer (pH 9.5). After stirring gently for 2 h
in the dark, 100 ml of a 4 mg/ml sodium borohydride solution was
added, and the mixture was reacted for 3 h at 4uC. At the end of
the reaction, the HRP-LD5 was dialyzed overnight against 0.15 M
PBS (pH 7.4) at 4uC and stored at 240uC.
Detection of HRP-LD5 binding to Ig molecules by ELISA
hIgG, hIgM and hIgA molecules were diluted in a coating
buffer (0.1 M NaHCO3, pH 9.6) to make a 10 mg/ml solution and
then coated onto a sterile 96-well microtiter plates at 37uC for 3 h.
After blocking the plates with blocking buffer (10% degreased milk
powder, 0.1% Tween 20 and 0.2% mercurothiolate in 0.01 M
PBS) for at least 2 h, 100 ml of 1:2 serial dilutions of 1 mg/ml
HRP-LD5 or HRP-goat anti-human PcAb were added to each
well and incubated for 45 min at 37uC. Plates were developed by
addition of 3, 3’, 5, 5’-tetramethylbenzidine (TMB) (Sigma, St.
Louis, MO, USA), and read at 450 nm with an ELISA Reader
(Bio Rad).
Detection of anti-HCV antibody
For detection of anti-HCV using HRP-LD5, the immunoassay
strips (Nunc, Rochester, NY, USA) were coated with 1.2 mgo f
each HCV Nucleocapsid/NS3/NS4/NS5 recombinant proteins
diluted in carbonate buffer (pH 9.6). The strips were maintained
at 37uC for 3 h and washed four times with a solution of PBS-
Tween 20 (PBST) and blocked with blocking buffer as above. The
strips were dried under reduced pressure for 2.5 h, and wrapped
individually with aluminum foil under vacuumed conditions,
which enable the precoated strips to be stored until use. Whenever
a serum specimen was received and ready for the diagnostic test, a
strip was removed from its wrapper and washed four times with
PBST. Then 100 ml of a 10-fold dilution of the serum specimen, a
blank, a positive and a negative reference serum sample were each
added to a separate well. The strip was then placed in a 37uC
incubator for 1 h. After washing four times with PBST, 100 mlo fa
1,000-fold dilution of HRP-LD5 (1 mg/ml) was added to the strip
and incubated for 45 min at 37uC. The strips were developed by
addition of TMB and read at 450 nm in an ELISA Reader. The
procedure for detection of anti-HCV IgG antibody was the same
as above except for the addition of HRP-conjugated anti-hIgG
instead of HRP-LD5. For anti-HCV IgM detection, goat anti-
human IgG (1:10) was added to the serum and the detection was
performed using HRP-conjugated anti-hIgM instead of HRP-
LD5. The anti-HCV detection by the three ELISA kits (Abbott 3.0
from Chicago, USA and both Ke Hua and Chang Zheng from
Shanghai, China) was performed according to the manufacturers’
instructions.
Confirmation of anti-HCV IgM
100 ml of the serum samples (diluted 1:10 in PBS) were treated
without or with b-mercaptoethanol (BME) at the concentration of
50 mM at 37uC for 30 min and then anti-HCV detection was
performed as above using HRP-LD5 assay, anti-HCV IgM assay
and Chang Zheng anti-HCV diagnostic ELISA kit.
Qualitative detection of HCV RNA
Reverse-transcriptase nested polymerase chain reaction (RT-
PCR) was performed for HCV RNA qualitative detection [10].
Anti-HCV IgM Detection with Enhanced Efficacy
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[11]. The first-strand cDNA of the highly conserved 5’-end
noncoding region [12] was synthesized by RT with an antisense
primer (5’-CCGGTCGTCCTGGCAATTCCGG-3’) and ampli-
fied by PCR with the same antisense primer and another sense
primer (5’-GGCGACACTCCACCATAGATCAC-3’). All oligo-
nucleotides were obtained from Shanghai Sangon Biological
Engineering Technology & Services Co., Ltd. (China). The PCR
conditions for 35 thermal cycles were 1 min at 94uC, 2 min at
42uC, and 2 min at 72uC, followed by a 5 min extension at 72uC
(Perkin Elmer Applied Biosystems, Foster City, CA, USA). PCR
products were analyzed by electrophoresis in a 1.2% agarose gel
and detected by staining with ethidium bromide.
Statistical analyses
Statistical analysis between the detection rates by different
diagnostic ELISA kits was performed by chi-square test. 95%
confidence intervals (95% CI) are presented for the detection rates.
A value of P,0.05 was considered statistically significant.
Results
NEIBM LD5 has significantly enhanced affinity for IgM
Our previous ELISA results had shown that LD5 molecules had
much stronger binding to human immunoglobulins (Igs) than SpA
[8]. In this study, binding properties of LD5 for human IgM, IgA
and IgG were further detected by SPR (Table 1). LD5 showed
high affinity for hIgG with an equilibrium dissociation constant
(KD) of 0.89 nM. Moreover, the affinity of LD5 binding to hIgM,
with a KD of 0.31 nM, was higher than that binding to hIgG and
reached the level of the binding of SpA with the hIgG. LD5 also
showed weak binding to hIgA (Table 1).
Binding properties of HRP-LD5 to human Igs
The LD5 conjugate HRP-LD5 was produced to compare its
human Igs binding properties with the binding of HRP-goat anti-
human PcAb, which is routinely used in most commercial anti-
HCV diagnostic ELISA kits. ELISA results showed that HRP-
LD5 had a much stronger binding reaction with hIgM and hIgA
than did HRP-goat anti-human PcAb, and had similar binding to
hIgG compared with HRP-goat anti-human PcAb (Fig. 1).
HRP-LD5 based EIA enhance the detection of anti-HCV
IgM
An anti-HCV ELISA assay was established using HRP-LD5 as
conjugate and 200 serum specimens from healthy blood donors
were tested to establish a cut-off value for this assay. The A450
values ranged from 0.017 to 0.093 (0.06260.023). Therefore,
0.200, the average plus 6-fold of the standard deviation value,
was chosen to distinguish positive from negative tests. This assay
was compared with two kinds of domestic diagnostic kits (Chang
Zheng and Ke Hua) and the Abbott 3.0 kit against the national
reference panel (Lot No. 0501) (Table 2). All 30 HCV-positive
reference serum samples were detected as positive with the HRP-
LD5 assay and with the Abbott 3.0 kit, whereas one was not
positive, according to the two domestic kit assays. All 30 HCV-
negative reference serum samples were negative in the domestic
kit assays, whereas one was detected as positive in Abbott 3.0 kit
and HRP-LD5 assays (Table 2). The relative sensitivity and
specificity of detection of the HRP-LD5 based assay and the
domestic diagnostic kits and Abbott 3.0 kit were above 96%,
which is the national standard for batch production quality
control.
To test the detection efficacy of the HRP-LD5 based assay, we
did a comparison study in an HCV high-risk population,
hemodialysis patients. We also established an anti-HCV IgG
assay and an anti-HCV IgM assay as reference tests. The cut-off
value of the anti-HCV IgG and anti-HCV IgM ELISA were
determined as above, and were 0.015 and 0.200 respectively.
Serum samples from 195 hemodialysis patients were measured
using the HRP-LD5 based assay, anti-HCV diagnostic ELISA kit
(Chang Zheng), the established anti-HCV IgG assay and anti-
HCV IgM assay (Fig. 2, Table 3). The results showed that the
HRP-LD5 assay had a statistically higher positive detection rate
(55.9% (109/195), 95% CI 0.489, 0.629) than that of a domestic
diagnostic ELISA kit (Chang Zheng) (53.3% (104/195), 95% CI
0.463, 0.603) (P-value,0.05), and 108 were positive according to
the anti-HCV IgG assay or the anti-HCV IgM assay. Interestingly,
104 samples that were positive using the anti-HCV IgG assay were
scored as being positive by both the HRP-LD5-based assay and
the Chang Zheng kit, and 33 were positive based on the anti-HCV
IgM assay. The five serum samples which were positive by HRP-
LD5 based assay and negative by Chang Zheng kit were also not
detectable by the Abbott 3.0 kit (data not shown). All of the five
positive for HRP-LD5 were positive for HCV RNA by RT-PCR
(data not shown). However, only four of the samples that produced
a false negative by the Chang Zheng kit were positive in the
established anti-HCV IgM assay. The serum samples of the five
patients that were false negative by the Chang Zheng kit were
collected again 3 weeks later and were positive according to the
Chang Zheng kit (Table 4) and the Abbott 3.0 kit (data not
shown).
To further verify that these five serum samples positive in the
HRP-LD5 based assay were due to specific anti-HCV IgM, the
IgM confirmation test for these samples and the samples from the
same patients three weeks later were performed. The A450 values
of all five original samples were negative when the samples were
treated with BME to destroy IgM (Table 4). The A450 values of
second set of samples dramatically decreased when measured with
both the HRP-LD5-based assay and the Chang Zheng kit when
the samples were treated with BME, and these decreases
corresponded well to the destruction of IgM as demonstrated by
IgM detection assay (Table 4). These results demonstrated that the
higher anti-HCV sensitivity of the HRP-LD5 based assay was due
to enhanced IgM detection.
Table 1. Kinetic constants of the LD5 and SpA binding to
three types of human Igs
1.
Analyte Constant Ligand
hIgG hIgM hIgA
LD5 ka(M
21s
21) (1.2260.06)610
5 (7.2360.07)610
4 (3.2460.04) 610
4
kd(s
21) (1.0860.05)
610
24
(2.2160.05)
610
25
(9.4460.11)
610
25
KD(nM) 0.8960.003 0.3160.01 2.9160.07
SpA ka(M
21s
21) (1.5460.12)610
5 (1.1560.13)610
5 (4.1660.23) 610
5
kd(s
21) (4.4060.31)
610
25
(8.1760.13)6
10
24
(2.9260.08)
610
23
KD(nM) 0.2960.01 7.1560.67 7.0360.22
1Binding experiments were performed by surface plasmon resonance with
serial 1:2 dilutions of LD5 and SpA from 1.25 and 0.8 mM for binding to hIgA,
hIgG and hIgM. ka, association rate constants; kd, dissociation rate constants;
KD, equilibrium dissociation constants. Data shown are averages 6 standard
deviation of three independent experiments.
doi:10.1371/journal.pone.0018477.t001
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The serologic window between HCV infection and the detection
of specific antibodies varies from patient to patient. With current
assays, seroconversion occurs on average between 7 and 8 weeks
after onset of an infection [13–15]. About 30% to 50% of patients
have undetectable anti-HCV antibodies at the onset of clinical
symptoms [16]. It is widely accepted that IgM provides a first line of
defense during microbial infections and IgM detection has proven
valuable for early diagnosis of many viral infections [17]. Therefore,
it is predicted that improved IgM detection by an anti-HCV EIA
assay may narrow this serologic window.
The IgM detection efficacy of current anti-HCV assays using
monoclonal or polyclonal HRP-labeled anti-human Ig antibodies
as conjugates has not been evaluated. In this study, we used a
NEIBM, LD5 which showed high affinity for IgM in addition to
Figure 1. The enzyme-labeled LD5 exhibits enhanced binding activities for IgM and IgA. The binding activities of horseradish peroxidase
(HRP)-labeled LD5 (HRP-LD5) or HRP-conjugated goat anti-human polyclonal antibodies (HRP-goat anti-human PcAb) to coated hIgM (A), hIgG (B) or
hIgA (C) were examined by ELISA. The coating buffer was used as solvent control.
doi:10.1371/journal.pone.0018477.g001
Table 2. Comparison of anti-HCV detection against the national reference panel of HRP-LD5 assay with three commercial
diagnostic kits.
HRP-conjugated
molecules
True
positive(a)
False
negative(b)
True
negative(c)
False
positive (d)
Sensitivity(%) a/(a+b)
(95% CI)
1
Specificity(%) c/(c+d)
(95% CI)
1
Relative accuracy (%)
(a+c)/(a+b+c+d)
Abbott 3.0 kit 30 0 29 1 100 (0.88–1.00) 96.66 (0.83–1.00) 98.33
Ke Hua kit 29 1 30 0 96.66 (0.83–1.00) 100 (0.88–1.00) 98.33
Chang Zheng kit 29 1 30 0 96.66 (0.83–1.00) 100 (0.88–1.00) 98.33
HRP-LD5 assay 30 0 29 1 100 (0.88–1.00) 96.66 (0.83–1.00) 98.33
195% CI, 95% confidence interval.
doi:10.1371/journal.pone.0018477.t002
Anti-HCV IgM Detection with Enhanced Efficacy
PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18477IgG (Table 1) [8], to make conjugates, HRP-LD5. The HRP-LD5
also expressed a much stronger binding capacity to hIgM than did
HRP-goat anti-human PcAb (Fig. 1). Consistently, the established
HRP-LD5-based anti-HCV assay showed a higher detection rate
than that of the commercial diagnostic kit (Chang Zheng) in
hemodialysis patients (Table 3, Fig. 2), and it was attributed to the
enhanced IgM detection (Table 3, Table 4).
Hemodialysis patients are a high-risk population for HCV
infection. The anti-HCV prevalence seen in these patients varied
from 3.3% in New Zealand [18], 39% in South America [19],
44%–60% in Far-Eastern countries [20] to as high as 80.0% in
Egypt [21]. HCV is highly transmissible among these patients, and
HCV infections at many different stages, including recent
infections, are observed in this population. Therefore, a compar-
ison study was conducted among them. Our results showed that
the HRP-LD5 based anti-HCV assay had a statistical significant
higher detection efficacy (55.9% positive detection rate) than did
the domestic diagnostic kit (Chang Zheng) (positive detection rate
Figure 2. Anti-HCV detection in 195 serum specimens from hemodialysis patients by different ELISA assays. ,A 450 values, with ELISA
cut-off values of either 0.150 indicated in solid line (established anti-HCV IgG assay and Chang Zheng anti-HCV diagnostic ELISA kit) or 0.200 indicated
in dotted line (established anti-HCV IgM assay and HRP-LD5 based assay).
doi:10.1371/journal.pone.0018477.g002
Table 3. Comparison of anti-HCV antibody detection in serum samples from 195 hemodialysis patients of HRP-LD5 based assay
with Chang Zheng anti-HCV kit.
The established anti-HCV IgG assay or IgM assay Chang Zheng kit HRP-LD5 assay
+ 2 + 2
IgG(+) or gM(+)
1 108(55.4%) 104(53.3%) 4 (2.1%) 108(55.4%) 0
95% CI
2 0.484–0.624 463–0.603 0.001–0.041 0.484–0.624
IgG(+), IgM(+)
1 33(16.9%) 33(16.9%) 0 33(16.9%) 0
95% CI
2 0.116–0.222 0.116–0.222 0.116–0.222
IgG(+), IgM(2)
1 71(36.4%) 71(36.4%) 0 71(36.4%) 0
95% CI
2 0.296–0.432 0.296–0.432 0.296–0.432
IgG(2), IgM(+)
1 4(2.1%) 0 0 4(2.1%) 0
95% CI
2 0.001–0.041 0.001–0.041
IgG(2), IgM(2)
1 87(44.6%) 0 87(44.6%) 1(0.5%) 86(44.1%)
95% CI
2 0.376–0.516 0.376–0.516 20.005–0.015 0.371–0.511
Total samples 195 104 91 109 86
1Data shown are the number of cases with each test result. Data shown in parentheses are the percentages of detected cases in the 195 total serum samples.
295% CI, 95% confidence interval.
doi:10.1371/journal.pone.0018477.t003
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with the 59.7% and 58.8% anti-HCV prevalence reported in other
Chinese hemodialysis patient studies [22,23].
The five patients who tested positive using the HRP-LD5 based
assay alone were demonstrated to have anti-HCV IgM antibodies
and HCV RNA. Follow-up samples taken from these patients
three weeks later were positive using both the HRP-LD5-based
assay and the Chang Zheng kit (Table 4). These results indicate
that these five patients were likely to be newly HCV infected cases,
which account for 2.56% of the 195 hemodialysis patients in this
study, consistent with the result in a follow-up study of Chinese
Shanghai hemodialysis patients that showed the anti-HCV
seroconversion rates at 6, 12, 18, 24 and 30 months were 6.4%,
11.9%, 20.7%, 35.4% and 54.5%, respectively [22].
Indirect EIAs have been developed to detect IgM against many
microbes. Low sensitivity or specificity is common problem for
IgM detection, and the lack of applicable anti-hIgM monoclonal
and polyclonal antibodies is a major obstacle for effective IgM
detection [24,25]. An indirect anti-HCV IgM EIA assay has also
been developed and extensively studied. Many reports have shown
it to be useful for early diagnosis of HCV infection [26–29],
whereas others do not support this conclusion [30,31]. For
unknown reasons, commercially available anti-IgM antibodies
have low affinity constants (Ka), varying from 2610
5 to
5.34610
8 M
21 [32], which is much lower than that of anti-hIgG
monoclonal and polyclonal antibodies, which is usually above
1610
9 M
21 [33–35]. Unlike the anti-IgM antibodies used in anti-
HCV IgM ELISA assay, LD5 has well defined binding mode, i.e.,
simultaneously bound to the k light chain and VH3 of hIgM.
Consequently, it showed a high binding affinity to hIgM with the
affinity constant (Ka) of 3.23610
9 M
21 and an equilibrium
dissociation constant (KD) of 0.31 nM, which was as high as that
of SpA to hIgG with the Ka of 3.45610
9 M
21 and the KD of
0.29 nM (Table 1). Consistent with this binding property, the
HRP-LD5 based assay displayed a higher IgM detection efficacy
than the established IgM assay (Table 3, Table 4).
To our knowledge, this is the first report of the application of an
NEIBM, LD5, to establish an anti-HCV detection assay with
enhanced detection efficacy due to improved IgM detection. Our
results also imply that NEIBMs with a high affinity to IgM could
have potential application for detection of antibodies against other
viral infections, such as hepatitis E virus or dengue virus, to
improve of detection efficacy and early diagnosis.
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